Administered as a subcutaneous weekly injection, it is a manifold single pharmacological agent that has the ability to significantly lower glucose levels, as well as improve insulin sensitivity, reduce weight and amend dyslipidemia favorably modifying the lipid profile
Federal Programs May Expand Access, But Timeline Is Unclear The Trump administration announced the BALANCE model in December 2025, which aims to expand access to GLP-1s in Medicare and Medicaid by negotiating lower prices with manufacturers
United States Maintains Market Leadership with Commercial Insurance Coverage Demand for obesity GLP-1 treatment in the United States is expanding at a CAGR of 25.4%, driven by growing commercial insurance coverage and strong consumer awareness of available treatments
It carries strategic Aib substitutions to resist DPP-4 cleavage and a C20 fatty di-acid chain at lysine-17 that drives reversible albumin binding extending the plasma half-life to roughly 6 days in published pre-clinical models and supporting once-weekly dosing protocols
Drug Saf 2008;31(6):469-484
